February is the shortest month, but there was still plenty of time for a rush of pharma and biotech hires, including a number of changes at the big pharmas, which may have slipped under your radar, given the chaotic news coming out of the United States.

二月是最短的一个月，但仍然有足够的时间让制药和生物技术行业迎来一波招聘热潮，包括大型制药公司的一系列人事变动。鉴于美国传出的混乱新闻，这些变动可能没有引起你的注意。

Catch up with our round-up of pharma and biotech hires from February 2025.

了解我们对2025年2月制药和生物技术领域招聘的汇总。

Cavazzoni leaves FDA for Pfizer, prompting ‘revolving door’ criticisms.

卡瓦佐尼离开FDA加入辉瑞，引发“旋转门”批评。

As we reported

正如我们所报道的

in a full article last month

在上个月的一整篇文章中

,

，

Patricia Cavazzoni

帕特里夏·卡瓦佐尼

joined Pfizer as chief medical officer after reisgning as head of the FDA's Center for Drug Evaluation and Research. Pfizer said that Cavazzoni will lead the group's regulatory, pharmacovigilance, safety, epidemiology, and medical information and evidence generation, among other medical functions, and will report to R&D chief Chris Boshoff.

在辞去FDA药物评估和研究中心主管一职后，加入了辉瑞公司担任首席医疗官。辉瑞表示，卡瓦佐尼将领导该集团的监管、药物警戒、安全、流行病学、医疗信息和证据生成等其他医疗职能，并将向研发主管克里斯·博绍夫汇报工作。

She succeeds Aida Habtezion, who is leaving the company..

她接替了即将离开公司的哈布特兹翁。

Boehringer Ingelheim taps long time Novo vet.

勃林格殷格翰任命诺和资深人士。

The month also saw

该月还出现了

Brian Hilberdink

布赖恩·希尔伯丁克

appointed president of US human pharma at Boehringer. Hilberdink most recently served a short stint as EVP at LEO Pharma, but before that he spent 26 years at Novo Nordisk, where he launched multiple blockbuster products and rare disease biologics.

被任命为勃林格殷格翰美国人类制药总裁。希尔伯丁克最近短暂担任了利奥制药的执行副总裁，但在那之前，他在诺和诺德工作了26年，在那里他推出了多个重磅产品和罕见病生物制品。

UCB and Novo Nordisk strengthen UK leadership.

UCB和诺和诺德加强英国领导地位。

Two top pharmas made big moves in their UK offices.

两家顶级制药公司在其英国办事处采取了重大行动。

Dr Stevan Shaw

斯特万·肖博士

was named head of UK research at UCB, while

被任命为UCB的英国研究主管，而

Sebnem Avsar Tuna

塞布内姆·阿夫萨尔·图纳

took on the role of UK general manager at Novo Nordisk. A researcher at UCB since 1993, Shaw succeeds

接任了诺和诺德英国总经理的职位。自1993年以来一直在UCB担任研究员的肖接任。

Dr Alistair Henry

艾利斯特·亨利博士

, who became chief scientific officer in October. As for Tuna, a two-decade veteran of Novo, she most recently led Asia-Pacific operations for the company.

，他于十月成为首席科学官。至于图纳，她是诺和公司工作了二十年的老员工，最近她领导了公司在亚太地区的运营。

New CEO in at Indivior.

Indivior迎来新任首席执行官。

Joe Ciaffoni

乔·西亚福尼

was appointed CEO of Indivior, a US-based global specialty pharma focused on treatments for opioid use disorder. Ciaffoni brings over 30 years of experience in pharma and biotech, having most recently served as president and CEO of Collegium Pharmaceutical. He has also held senior positions at Endo International, Biogen, and Shionogi.

被任命为总部位于美国的全球专业制药公司Indivior的首席执行官，该公司专注于治疗阿片类药物使用障碍。Ciaffoni在制药和生物技术领域拥有超过30年的经验，最近曾担任Collegium Pharmaceutical的总裁兼首席执行官。他还曾在Endo International、Biogen和Shionogi担任高级职位。

.

。

Click here for our full coverage

点击这里获取我们的全面报道

.

。

FreeOx Biotech expands leadership team.

FreeOx生物技术公司扩大了领导团队。

FreeOx Biotech, a clinical-stage biopharmaceutical company developing a new drug class for the emergency treatment of acute ischaemic stroke (AIS) patients, made several key appointments in February.

FreeOx Biotech是一家临床阶段的生物制药公司，致力于开发用于急性缺血性中风（AIS）患者紧急治疗的新型药物，在二月进行了多项关键任命。

Pat Nasshorn

帕特·纳什霍恩

joined as chief business development officer, bringing experience from Merck, Johnson & Johnson, and Bristol-Myers Squibb.

加入公司担任首席业务发展官，带来了默克、强生和百时美施贵宝的工作经验。

Dr Ian Hitchcock

伊恩·希区柯克博士

was named chief development officer. His 25-year career includes senior roles at Abbott, Bristol-Myers Squibb, Pharmion/Celgene, and Aimmune.

被任命为首席开发官。他25年的职业生涯中曾在雅培、百时美施贵宝、Pharmion/Celgene和Aimmune担任高级职务。

Dr Jina Swartz

施瓦茨·吉娜博士

who has worked in academic neurology and global clinical development, including roles at Merck, Takeda, Eisai, and GSK, was named chief medical officer.

曾在学术神经病学和全球临床开发领域工作过，包括在默克、武田、卫材和葛兰素史克担任职务，被任命为首席医学官。

Ona Therapeutics adds two to C-Suite.

Ona Therapeutics在C级管理层新增两人。

Ona Therapeutics, a Barcelona-based biotech working on novel antibody-drug conjugates, named

总部位于巴塞罗那的生物技术公司 Ona Therapeutics 专注于新型抗体药物偶联物的研究，命名为

Stéphane Durant des Aulnois

斯特凡·杜兰·德·奥尔努瓦

as its new chief financial officer. Durant des Aulnois spent nine years in finance roles at Ipsen. Additionally,

作为其新任首席财务官。杜兰特·德·奥尔努瓦在益普生担任了九年的财务职务。此外，

Dr Jutta Amersdorffer

朱塔·阿默斯多费尔博士

joined as chief medical officer, having held multiple clinical and managerial roles at Sandoz, MorphoSys, and Otsuka Novel Products.

加入公司担任首席医疗官，曾在山德士、MorphoSys 和大冢新制品公司担任多个临床和管理职务。

Two more C-Suite business appointments.

两起更多的C级商业任命。

Two biotechs added executives on the business side.

两家生物技术公司在业务部门增加了高管。

Gad Soffer

加德·索弗

was named chief business officer at LB Pharma, a New York clinical-stage biopharma developing novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia. While in a former role at Rheos, Soffer landed a $700M strategic collaboration with Roche. And

被任命为纽约临床阶段生物制药公司LB Pharma的首席业务官，该公司致力于开发治疗神经精神疾病（包括精神分裂症）的新型疗法。在之前任职于Rheos期间，Soffer达成了与罗氏公司的7亿美元战略合作伙伴关系。

Dr Matthew Norkunas

马修·诺尔库纳斯博士

joined Tubulis as chief financial officer and president. Norkunas brings extensive experience in financial leadership within the life sciences industry, having served as CFO at publicly listed and private biotech companies, including Generation Bio and SomaLogic. Tubulis is a Munich and Cambridge, MA-based innovator in antibody-drug conjugates..

诺库纳斯加入Tubulis担任首席财务官兼总裁。他在生命科学行业的财务领导方面拥有丰富经验，曾担任多家上市和私有生物技术公司的首席财务官，包括Generation Bio和SomaLogic。Tubulis是一家总部位于慕尼黑和马萨诸塞州剑桥的抗体药物偶联物领域的创新企业。

Aspargo Labs adds regulatory expert to leadership team.

Aspargo Labs 增加了监管专家加入领导团队。

Aspargo Labs, a New York specialty pharma and med tech company converting existing medications to liquid oral suspensions delivered via a connected device, named

Aspargo Labs，一家纽约的专业制药和医疗技术公司，将现有药物转化为通过连接设备递送的液体口服悬浮液，命名为

Mario Guralnik

马里奥·古拉尔尼克

chief regulatory officer. Guralnik brings regulatory affairs experience from Amgen, as well as extensive involvement with FDA advisory boards and industry committees.

首席监管官。古拉尼克带来了他在安进公司的监管事务经验，以及与FDA咨询委员会和行业委员会的广泛参与。

Three SVPs round out February hires.

三位高级副总裁完成了二月份的招聘。

Ottimo Pharma, a London- and Boston-based biotech developing dual-pathway antibodies to treat cancer, announced two senior vice president hires, while New York biopharma LB Pharma announced one more.

总部位于伦敦和波士顿的生物技术公司 Ottimo Pharma 专注于开发双通路抗体治疗癌症，宣布了两位高级副总裁的任命，而纽约生物制药公司 LB Pharma 也宣布了一项人事任命。

Dr Katherine Bell-McGuinn

凯瑟琳·贝尔-麦奎因博士

joined Ottimo as SVP clinical development. She has held leadership roles at 858 Therapeutics, Lilly, and Abbvie, where she led oncology early development.

加入Ottimo担任临床开发高级副总裁。她曾在858 Therapeutics、礼来和艾伯维担任领导职务，主导肿瘤学早期开发工作。

Robert Tighe

罗伯特·蒂格

was appointed Ottimo’s SVP preclinical and translational sciences. The former chief scientific officer at Ankyra Therapeutics, Tighe boasts more than 20 years of oncology experience.

被任命为Ottimo的高级副总裁，负责临床前和转化科学。Tighe曾在Ankyra Therapeutics担任首席科学官，拥有超过20年的肿瘤学经验。

Richard Silva

理查德·席尔瓦

joined LB Pharma as SVP technical operations. Silva most recently served as SVP pharmaceutical sciences at Carmot Therapeutics, now a part of Roche.

加入LB制药公司担任技术运营高级副总裁。席尔瓦最近曾担任Carmot Therapeutics制药科学高级副总裁，该公司现已成为罗氏的一部分。

That’s it for our pharma and biotech hires, but stay tuned for our other hires round-ups and remember, you can send your own hires to

以上就是我们制药和生物技术领域的招聘信息，但请继续关注我们的其他招聘汇总，记住，您可以将自己的招聘信息发送到

editorial@pharmaphorum.com

编辑部@药坛.com

for inclusion in this column.

列入本专栏。